China's National Medical Products Administration approved the neostigmine methylsulfate injection produced by ApicHope Pharmaceutical (SHE:300723) subsidiary Guangzhou Lianrui Pharmaceutical, according to a Saturday filing with the Shenzhen bourse.
Shares closed 1% lower on Monday.
The drug is indicated for the treatment of myasthenia gravis or weakness in voluntary muscles, postoperative flatulence or farting, and urinary retention, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments